Dabigatran

From Citizendium
Revision as of 12:29, 21 September 2009 by imported>Robert Badgett (New page: In medicine, '''dabigatran''' is an anticoagulant that is a direct thrombin inhibitor<ref>{{MeSH}}</ref> In 2009, dabigatran, a direct thrombin inhibitors, was compare...)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

In medicine, dabigatran is an anticoagulant that is a direct thrombin inhibitor[1]

In 2009, dabigatran, a direct thrombin inhibitors, was compared to warfarin in the RE-LY randomized controlled trial.[2]

Dabigatran versus warfarin for atrial fibrillation[2]
Intervention Outcomes
Stroke or systemic embolism Major bleeding Mortality
Dabigatran 110 mg twice daily 1.53% 2.71% 3.75%
Dabigatran 150 mg twice daily 1.11% 3.11% 3.64%
Warfarin 1.69% 3.36% 4.13%
† p < 0.05 as compared to warfarin group

References

  1. Anonymous (2024), Dabigatran (English). Medical Subject Headings. U.S. National Library of Medicine.
  2. 2.0 2.1 Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A et al. (2009). "Dabigatran versus Warfarin in Patients with Atrial Fibrillation.". N Engl J Med 361 (12): 1139-1151. DOI:10.1056/NEJMoa0905561. PMID 19717844. Research Blogging.